S 81694

Drug Profile

S 81694

Alternative Names: NMS P153; S81694

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Servier
  • Class Antineoplastics; Small molecules
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 22 Nov 2017 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease) in Netherlands (IV) (EudraCT2017-002459-27)
  • 01 Dec 2016 Servier re-initiates a phase-I trial in Solid tumours (Late-stage disease, Metastatic disease) in Netherlands and Belgium (IV) (ISRCTN35641359)
  • 24 Sep 2015 S 81694 is acquired by Servier
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top